Iceland· IS-EU/1/11/749/002
Caprelsa
A vandetanib product containing vandetanibum inn, registered in Iceland by Esteve Pharmaceuticals S.A.. The same ATC class is registered in 13 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Vandetanib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01EX04 (vandetanib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Vandetanib · ATC L01EX04
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of vandetanib costs, country by country.
Normalised to the WHO defined daily dose (0.3 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Vandetanib · price per daily dose (0.3 g)
USD · FX 28 Sept 2026
- CH Switzerland$239.02
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Vandetanibum INN
- Manufacturer
- Esteve Pharmaceuticals S.A.
- Country
- Iceland (IS)
- ATC code
- L01EX04
- ATC class
- Vandetanib
- Defined daily dose
- 0.3 g, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean59297730 stk x1 þpakkiISK 809674
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
351 interactions on record for vandetanib.
Graded by severity as the source publishes them — 244 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Vandetanib · interactions on record
351 records
- 244 severe
- 95 moderate
- 12 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Vandetanib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumCaprelsa 300 mgEsteve Pharmaceuticals
- CzechiaCAPRELSAEsteve Pharmaceuticals S.A., Barcelona
- SpainCAPRELSA 300 MG COMPRIMIDOS RECUBIERTOS CON PELICULAEsteve Pharmaceuticals S.A.
- FinlandCaprelsaEsteve Pharmaceuticals S.A.S.
- FranceCAPRELSA 300 mg, comprimé pelliculéESTEVE PHARMACEUTICALS (ESPAGNE)
- IrelandCaprelsa 300 mg film-coated tabletsEsteve Pharmaceuticals S.A.
- NetherlandsCaprelsa, 300 mg filmomhulde tablettenEsteve Pharmaceuticals S.A.
- NorwayCaprelsaEsteve Pharmaceuticals S.A
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Caprelsa
- Norway · Caprelsa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/9ec67bd0-9d1f-431d-b7e3-8485ec4a93bb GET /v1/drugs/9ec67bd0-9d1f-431d-b7e3-8485ec4a93bb?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01EX04",
"marketed": true,
"strength": "300 mg",
"ma_number": "EU/1/11/749/002",
"substance": "Vandetanibum INN",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í krabbameinslækningum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.\r\nHámarksmagn á lyfseðli er ein pakkning og ekki er heimilt að lyfseðill sé fjölnota.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "40956"
}See everything about vandetanib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.